Dan Janiak Joins OncoC4 as Chief Business Officer
2 reports, 2 independent
Updated Mon 00:00
Still developing
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Dan Janiak was appointed Chief Business Officer at OncoC4, Inc. on November 2, 2026. Janiak previously served as Executive Director, Business Development at AstraZeneca, where he led oncology platform transactions involving artificial intelligence and machine learning. He brings over 15 years of experience building and scaling biotechnology companies across oncology and rare diseases.
Why it matters
Janiak's background in executing complex transactions and developing corporate strategy is expected to be valuable as OncoC4 advances its pipeline. His experience could help the company pursue opportunities to maximize the value of its innovative therapies.
Who's involved
- AstraZenecaFormer employer of Dan Janiak, where he led oncology platform transactions.
- Bristol-Myers SquibbNot involved in this event.
- AbbVieNot involved in this event.
- TempusNot involved in this event.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
-
AstraZeneca
British-Swedish pharmaceutical company